The role of antibiotics in the treatment of chronic prostatitis: A consensus statement by Bjerklund Johansen, T. E. et al.
Clinical Paper
Eur Urol 1998;34:457–466
The Role of Antibiotics in the
Treatment of Chronic Prostatitis:
A Consensus Statement
T.E. Bjerklund Johansena
R.N. Grünebergb
J. Guibert c
A. Hofstetterd
B. Lobele
K.G. Naber f
J. Palou Redorta g
P.J. van Canghh
a Section of Urology, Norwegian Institute of
Urology, University of Tromsø, Porsgrunn,
Norway;
b Department of Microbiology,
University College Hospital, London, UK;
c Hôpital Saint Joseph, Paris, France;
d Urologische Klinik und Poliklinik,
Klinikum Grosshadern,
Ludwig Maximilians University, Munich,
Germany;
e Service d’Urologie,
Hôpital de Pontchaillou, Rennes, France;
f Urologic Clinic, Technical University of
Munich, Germany;
g Fundacio Puigvert, L’Institut d’Urologiea,
Universitat Autonoma de Barcelona,
Barcelona, Spain;
h Urology Department, Cliniques
Universitaires St Luc, Bruxelles, Belgium
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Key Words
Chronic prostatitis
Treatment
Antibiotics
Guidelines
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
Abstract
Practical guidelines for the diagnosis and treatment of chronic prostatitis are
presented. Chronic prostatitis is classified as chronic bacterial prostatitis (cul-
ture-positive) and chronic inflammatory prostatitis (culture-negative). If
chronic bacterial prostatitis is suspected, based on relevant symptoms or
recurrent UTIs, underlying urological conditions should be excluded by the
following tests: rectal examination, midstream urine culture and residual
urine. The diagnosis should be confirmed by the Meares and Stamey tech-
nique. Antibiotic therapy is recommended for acute exacerbations of chronic
prostatitis, chronic bacterial prostatitis and chronic inflammatory prostatitis,
if there is clinical, bacteriological or supporting immunological evidence of
prostate infection. Unless a patient presents with fever, antibiotic treatment
should not be initiated immediately except in cases of acute prostatitis or
acute episodes in a patient with chronic bacterial prostatitis. The work-up,
with the appropriate investigations should be done first, within a reasonable
time period which, preferably, should not be longer than 1 week. During this
period, nonspecific treatment, such as appropriate analgesia to relieve symp-
toms, should be given. The minimum duration of antibiotic treatment should
be 2–4 weeks. If there is no improvement in symptoms, treatment should be
stopped and reconsidered. However, if there is improvement, it should be con-
tinued for at least a further 2–4 weeks to achieve clinical cure and, hopefully,
eradication of the causative pathogen. Antibiotic treatment should not be giv-
en for 6–8 weeks without an appraisal of its effectiveness. Currently used anti-
biotics are reviewed. Of these, the fluoroquinolones ofloxacin and ciprofloxa-
cin are recommended because of their favourable antibacterial spectrum and
pharmacokinetic profile. A number of clinical trials are recommended and a
standard study design is proposed to help resolve some outstanding issues.
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Introduction
Although a number of papers have been published with
the aim of clarifying the diagnostic and therapeutic prob-
lems associated with chronic prostatitis, there is still a
need for a set of clear practical guidelines for use by all
physicians involved in the diagnosis and treatment of
chronic prostatitis, but particularly for use by the general
practitioner and the general clinician to whom such
patients are most likely to present first. This paper aims to
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Table 1. Classification of chronic prostatitis1
Chronic bacterial
prostatitis
Significant prostatic inflammation
Isolation of an aetiologically recognized
organism from the prostatic fluid/urine
Chronic abacterial Significant prostatic inflammation
(nonbacterial)
prostatitis
Failure to isolate an organism from the
prostatic fluid/urine, or isolation of an
organism whose aetiological significance is
debatable
Prostatodynia No significant prostatic inflammation
Failure to isolate an organism from the
prostatic fluid/urine
1 Classification using the Meares and Stamey localization tech-
nique adapted from Drach et al. [8].
fulfil this need, by presenting the results of a consensus
meeting on the aetiology, diagnosis and therapy of chronic
prostatitis. Issues relating to fungal and viral prostatitis
will not be covered.
Prostatitis, which is associated with a number of signs
and symptoms in the pelvic region, is a widespread condi-
tion in men with an estimated prevalence of 10% [1]. It
has been estimated that approximately half the adult male
population will experience symptoms of prostatitis at
some point [2, 3] and that it results in about 25% of all
visits to a urologist [4]. Although it is a common diagno-
sis, chronic prostatitis is poorly characterized and the
aetiology is not always clear, with only 5–10% of cases
having an identifiable microbial cause [5]. The most com-
mon pathogen is Escherichia coli, accounting for 80% of
cases of chronic bacterial prostatitis. Klebsiella spp., Pro-
teus spp., Enterococcus faecalis and Pseudomonas aerugi-
nosa occur less frequently.
Antibiotic therapy is usually prescribed where there is
good clinical, bacteriological or immunological evidence
of infection, and the choice of antimicrobial agent is
based upon its activity against the known or strongly sus-
pected causative pathogen(s), and upon its ability to reach
the site of infection in adequate concentrations.
In acute prostatitis, application of these principles is
relatively easy, since the clinical presentation of this con-
dition is generally well defined, the aetiology well estab-
lished, bacteriological confirmation of infection almost
always obtained [6], and most antibiotics achieve thera-
peutically significant levels in the acute inflamed prostatic
tissue. However, in chronic prostatitis, the exact opposite
is true.
The definition of chronic prostatitis is complicated for
a number of reasons. Firstly, chronic prostatitis is not a
single condition, but a term that is loosely used to describe
a group of conditions causing genito-pelvic pain and uri-
nary dysfunction in adult men [7]. The generally accepted
classification of chronic prostatitis, introduced by Drach
et al. [8] in 1978, divides cases into chronic bacterial pros-
tatitis (CBP), abacterial chronic prostatitis (ACP) and
prostatodynia, according to the degree of prostate inflam-
mation, and the microbiological results of expressed pros-
tatic secretions (EPS) and midstream urine samples (ta-
ble 1).
Secondly, the differential diagnosis of these various
forms is impossible on clinical grounds alone [9] since
their clinical presentation varies widely, and is often simi-
lar to that of other diagnoses. It is also impossible to make
a diagnosis by examining the EPS in isolation due to
unavoidable contamination from the urethra [9]. Thirdly,
the most accurate test currently available for the differ-
ential diagnosis of chronic prostatitis, the Meares and Sta-
mey localization technique [10], is rarely used by clini-
cians because it has low sensitivity, its interpretation cri-
teria are, as yet, not unambiguously defined, it is time-
consuming, relatively expensive, and patient-invasive [6,
7, 11, 12]. However, despite these shortcomings, it re-
mains a fundamental diagnostic tool in clinical trials of
chronic prostatitis.
Fourthly, diagnosis is complicated by the fact that an
aetiologically recognized pathogen, such as E. coli, Klebsi-
ella spp., Proteus spp., E. faecalis or P. aeruginosa, is only
isolated from 5 to 10% of patients with chronic prostatitis
[5]. In the majority of patients, bacteriological evaluation
of prostatic fluid either fails to identify a pathogen or
identifies an organism of debatable significance, for ex-
ample, Chlamydia trachomatis, Ureaplasma urealyticum
and Mycoplasma hominis, even though in many of these
patients (60%) significant prostatic inflammation can be
demonstrated (leucocyte counts in EPS of 110/hpf or
11,000/Ìl) [7, 11].
In addition to the diagnostic difficulties associated
with this condition, response rates obtained in clinical
trials of CBP are frequently poor, even though the patho-
gens were shown to be highly sensitive in vitro to the anti-
biotic used, and remained so at the end of treatment [13].
This is thought to be primarily due to the inability of the
antibiotic prescribed to achieve adequate concentrations
in the prostatic site of infection.
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Fig. 1. Recommended classification of
chronic prostatitis according to bacteriologi-
cal results.
Chronic prostatitis
Chronic bacterial prostatitis Chronic inflammatory prostatitis
(Culture-positive) (Culture-negative)
Pathogen demonstrated No pathogen demonstrated
(includes ‘typical’ and ‘atypical’ pathogens) (includes ‘typical’ and ‘atypical’ pathogens)
Definition of Chronic Prostatitis Suitable for
Antibiotic Treatment
A diagnosis of chronic prostatitis should only be made
if the appropriate investigations, such as the Meares and
Stamey localization technique, and correct culture meth-
ods have been performed. Chronic prostatitis can then be
divided into culture-positive (CBP) where a pathogen can
be isolated, and culture-negative (chronic inflammatory
prostatitis) where no pathogen can be demonstrated
(fig. 1). It is important, however, to state that this defini-
tion of culture-negative prostatitis does not exclude the
possibility of a bacterial cause, since it simply means that,
with current methods and knowledge, a bacterial cause
cannot be identified.
The so-called ‘atypical’ bacteria, Mycoplasma, Urea-
plasma and Chlamydia, have a debatable role in this dis-
ease. That they are present is not in dispute but whether
they are causative pathogens in this condition is not clear.
However, we conclude that these ‘atypical’ bacteria
should be included in the definition of CBP because they
are, by definition, bacteria, but their significance, in rela-
tion to the disease, is open to question.
Another classification of prostatitis was introduced by
a Workshop Committee of the National Institute of Dia-
betes and Digestive and Kidney Diseases (NIDDK) in
1995 [14] as the NIDDK reference standard for research
studies. The NIDDK classification is as follows:
I. Acute bacterial prostatitis (acute infection of the
prostate).
II. Chronic bacterial prostatitis (recurrent infection of
the prostate).
III. Chronic abacterial prostatitis – chronic pelvic pain
syndrome (CPPS) (no demonstrable infection). IIIA. In-
flammatory CPPS (white cells in semen/EPS/voided blad-
der urine-3 (VB-3)). IIIB. Noninflammatory CPPS (no
white cells in semen/EPS/VB-3).
IV. Asymptomatic inflammatory prostatitis (AIP) (no
subjective symptoms, detected either by prostate biopsy
or the presence of white blood cells in prostate secretions
during evaluation for other disorders).
This classification uses the same principles (presence
or absence of white blood cells and/or pathogens) as
defined by the localization technique of Meares and Sta-
mey [10] and histology. Category IIIA corresponds to
abacterial prostatitis and IIIB to prostatodynia. Thus, the
term ‘prostatitis’ is only used for patients with acute,
chronic or recurrent bacterial prostatitis in whom causa-
tive pathogens can be identified. The term ‘pelvic pain
syndrome’ indicates that it is not known whether or not
the symptoms are related to the prostate. This reflects the
present state of knowledge and the clinical situation. The
main purpose for the NIDDK classification is to improve
the study of CPPS, which is the most prevalent of the
symptomatic diseases. The present paper, however, con-
centrates in more detail on the indication for and manage-
ment of antimicrobial therapy if causative pathogens
have been demonstrated or are reasonably suspected. The
first two categories, acute and chronic (recurrent) bacte-
rial prostatitis, are the same in both the NIDDK and our
classification. We have used a classification based on that
of Drach et al. [8] since this is widely accepted.
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Fig. 2. Flow chart of recommended diagnostic procedures for a patient presenting with suspected chronic pros-
tatitis.
Table 2. Clinical symptoms characterizing chronic prostatitis1
Frequent need to urinate
Difficulty urinating, e.g. weak stream and straining
Pain on urination, or that increases with urination
Fatigue
Pain (other than with urination) in the pelvic area
Pain in the lower back
Abdominal pain
Arthralgia
Myalgia
Pain at other location
1 Adapted from Alexander and Trissel [15].
Clinical Presentation
CBP should be suspected if the patient presents with
either relevant symptoms (table 2) [15], recurrent urinary
tract infection or urinary tract infection that fails to
respond to treatment. However, before antibiotic therapy
is initiated, a number of investigations should be per-
formed to confirm the diagnosis. For the diagnosis of
prostatitis, there must be a correlation with inflamma-
tion, not just the symptoms. The main parameter for diag-
nosing inflammation in the male urogenital tract is in-
creased leucocytes in the prostatic fluid and possible sup-
porting parameters are complement C3, coeruloplasmin
or PMN-elastase in the ejaculate [16].
An exception to this ‘rule’ applies to the patient whose
presenting symptoms are indicative of an acute prostatitis
or an acute, mainly febrile, episode against a background
of chronic prostatitis, i.e. a sudden onset of fever and
acute lower urinary tract symptoms and/or urinary reten-
tion. Such an acute exacerbation can be a serious illness
and requires immediate antibiotic therapy. Digital rectal
examination may be useful in acute or severe, febrile pros-
tatitis since the prostate gland is often tender and swollen,
whereas in chronic prostatitis it is usually normal [6].
Recommended Diagnostic Procedures
For the general clinician, it is important to distinguish
between chronic prostatitis and other conditions which
require a different treatment approach: other organic dis-
eases, such as carcinoma in situ and bladder tumours, pel-
vic floor irritation or spasms, those patients with clinically
acute prostatitis, as defined above, who then may develop
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chronic prostatitis, and patients who have a lower UTI.
Urine cytology screening should be performed to exclude
malignancies [17]. Figure 2 shows a flow chart of the rec-
ommended procedures.
A patient suspected of having chronic prostatitis
should have a urological and proctorectal examination, to
rule out underlying urological or proctohaemorrhoidal
diseases [18]. These basic clinical investigations should be
a rectal examination, midstream urine culture and residu-
al urine. If the results of these tests are normal, underlying
urological conditions can be mostly excluded. However, if
the results are abnormal, the patient should be referred to
a urologist or proctologist, as appropriate, for further
examination. Further tests would include urodynamics,
ultrasound, radiography, cystoscopy, proctoscopy, etc.
The possibility of prostate cancer should be excluded by
serial prostate-specific antigen (PSA) measurements and/
or biopsy in patients considered to be at risk or with a
family history of cancer. If elevated PSA levels are found
together with symptoms of prostatitis, the PSA should be
controlled after a few weeks of antibiotic treatment. Cul-
ture-negative patients with macro- or microhaematuria, a
sign of possible bladder carcinoma, should be referred to a
urologist to rule out organic disease [19].
If no abnormalities are found and the segmented cul-
ture technique (Meares and Stamey [10]) can localize
inflammation to the prostate, the diagnosis of chronic
prostatitis can be confirmed. However, although the
Meares and Stamey technique is currently the most accu-
rate way of confirming the diagnosis of prostate infection,
it is not used routinely by all physicians in clinical prac-
tice.
Patients Recommended for Antibiotic Therapy
Once the possibility of other underlying causes for the
clinical presentation has been excluded, we recommend
that all patients with chronic prostatitis, i.e. both culture-
positive and culture-negative, should receive antibiotic
therapy, although the choice of agent will vary according
to the culture results. There can be little debate concern-
ing the treatment of CBP where a ‘typical’ pathogen is iso-
lated from the site of infection. However, the recommen-
dation for antibiotic therapy in culture-negative cases
(chronic inflammatory prostatitis) and cases where an
‘atypical’ organism is isolated, is contrary to that suggest-
ed by some authors [11, 20].
Whilst there is considerable evidence demonstrating
that ‘atypical’ bacteria are present, their aetiological role
in chronic prostatitis remains questionable. Diagnostic
and culture techniques need to be refined so that the
pathogenic role of these ‘atypical’ bacteria can be defined
[9].
The justification for this is that failure to isolate a bac-
terium does not necessarily mean that one is not present
and there is a reasonable possibility that a good clinical
response can be achieved. A negative culture result may
arise as a consequence of sampling errors, or poor culture
or detection techniques [20]. This recommendation is
supported by clinical evidence showing that culture-nega-
tive cases of chronic prostatitis do respond to antibiotic
treatment [11, 21]. If there is clinical and immunological
evidence of infection, we consider that antibiotic therapy
should be tried in culture-negative cases.
In culture-negative prostatitis, antibiotics should not
be given for more than 2 weeks unless the patient is
improving. If there is no improvement, the antibiotic
should be stopped and the treatment reconsidered. Cau-
tion should be exercised in treating these patients and
they should be followed closely. If the assumption is that
this is prostatitis, e.g. by the evidence of improvement
after initiation of antibiotic therapy, but a bacterium can-
not be grown, there is still a duty of care to that patient to
treat them for the same length of time as a culture-positive
prostatitis patient would be treated. It would be illogical
to treat a culture-negative patient for a shorter period of
time. Therefore, as stated below, if there is improvement,
treatment should be continued for at least a further 2–4
weeks. However, it is important that antibiotic treatment
should not be continued for 6–8 weeks without any
appraisal of whether it is effective.
Principles of Antibiotic Treatment in Chronic
Prostatitis
Antibacterial Activity
The choice of antibacterial therapy should be based
upon the pathogen and its sensitivity together with the
pharmacokinetics of the drug. In CBP, since bacteriologi-
cal confirmation of the causative pathogen is obtained,
the antibacterial cover required is apparent. However, in
chronic inflammatory prostatitis, where no bacteria are
identified, antibiotic therapy is prescribed on an empiri-
cal basis, and as such should provide cover against both
‘typical’ and ‘atypical’ pathogens. A logical choice of anti-
biotic for empirical therapy would therefore be one which
has a broad spectrum of activity against the most probable
pathogens. A further consideration is the low growth rate
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of bacteria in chronic prostatitis. Some antibiotics, such
as ß-lactams, are only active when bacteria are multiply-
ing rapidly.
Antibiotic Levels in Prostatic Tissue
A basic consideration in the choice of an antibiotic, in
terms of its pharmacokinetics, is how well it penetrates to
the site of prostatic infection. Most antibiotics that are
active against urinary tract pathogens diffuse poorly into
prostatic fluid and tissue. In order to diffuse into the site
of prostatic infection, an antibiotic must be lipid-soluble,
a weak base and have a dissociation coefficient (pKa)
such that it is nonionized in plasma and able to ionize in
the acidic environment of the prostatic fluid, thereby
being preferentially concentrated in the prostatic fluid by
ionic trapping. Unfortunately, few antibiotics have these
necessary characteristics to be of use in the treatment of
chronic prostatitis. In addition, some studies have indi-
cated that the pH of prostatic fluid in CBP patients is
alkaline rather than acidic [22–24]. The fluoroquinolones
have an advantage in this respect because they are am-
photeric drugs or zwitterions and thus have two pKa val-
ues, one at acid pH and one at alkaline pH.
The diffusion of an antibiotic into the prostatic site of
infection is a critical factor in determining its effective-
ness in treatment [25]. It is considered to be the major
contributing factor explaining the poor response rates
achieved with many antibiotics in clinical trials of CBP,
since the pathogens in these studies had been shown to be
highly sensitive in vitro to the antibiotic used, and
remained so at the end of treatment [13]. In acute prosta-
titis, however, the situation is different and the intense
inflammation which occurs allows many antibiotics to
penetrate prostate gland readily.
Initiation of Treatment
Unless a patient presents with fever, with or without
acute lower urinary tract symptoms, antibiotic treatment
should not be initiated immediately at the first patient
visit. Antibiotic treatment should only be started imme-
diately in cases of acute prostatitis or an acute, mainly
febrile, episode in a patient with CBP. The work-up, with
the appropriate investigations, should be done first. If
fever and acute urinary symptoms are absent, there is no
requirement to give an antibiotic immediately. Generally,
patients with chronic prostatitis have had the symptoms
for a considerable time and therefore there is not the
urgency to begin antibiotic treatment straight away. The
work-up should be done within a reasonable time period
which, preferably, should not be longer than 1–2 weeks.
During this period, nonspecific treatment, such as appro-
priate analgesia to relieve symptoms, should be given
while the diagnosis is confirmed. Initiating antibiotic
treatment before the diagnosis is confirmed may produce
false-negative test results.
Dosage
The dose will depend on which antibiotic is used and
dose recommendations vary greatly from country to coun-
try. However, it is important to emphasize that the maxi-
mum dose available of the chosen antibiotic is required in
order to ensure that adequate concentrations are achieved
in the prostatic site of infection.
Length of Treatment
As with other chronic conditions, the duration of treat-
ment required for chronic prostatitis is relatively long and
an ‘adequate’ course of treatment should be given. This is
because, in CBP, bacteria are found in small, isolated
microcolonies deep within the acini and ducts of the pros-
tate. In addition, some causative organisms, such as Chla-
mydia, are intracellular pathogens. It has been suggested
that a significant factor contributing to the failure of anti-
biotic therapy in CBP is the difficulty of eradicating bac-
teria in protected microcolonies within an infection-
induced altered microenvironment within the prostate
gland [26]. There is great variation in the duration of
treatment of chronic prostatitis which ranges in clinical
studies from a few days to several months [27]. We recom-
mend that the minimum duration of treatment should be
2–4 weeks. If there is no improvement in symptoms after
this time, the treatment should be stopped and recon-
sidered. However, if there is improvement, treatment
should be continued for at least a further 2–4 weeks to
achieve clinical cure and, it is hoped, eradication of the
causative pathogen. If the patient has not improved by
this stage, expert advice from a urologist should be sought.
If the patient is being treated by a general practitioner, the
recommendation is that the patient should be referred to a
urologist if there is a treatment failure after 2 weeks of
therapy. Antibiotic treatment should not be continued for
6–8 weeks without any appraisal of whether the treatment
is effective.
Cost
Most antibiotics will be given for a similar length of
time to treat chronic prostatitis. Therefore, the cost of
antibiotic treatment is a question of cost as an intrinsic
characteristic of the drug, that is, the cost per day to give a
drug, not just in drug acquisition terms, but also in terms
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Table 3. The advantages and disadvantages of antibiotics currently prescribed in CBP
Antibiotic Advantages Disadvantages Recommendation
Good activity against Gram-negative Parenteral formulation only Not recommended
bacteria Dose-related toxicity
Need for monitoring (if 12 or 3 doses)
Inadequate activity against Gram-positive
bacteria
Oral ß-lactams Comparatively nontoxic
Incidence of serious adverse events rare
Monitoring unnecessary
Sensitivity to amoxycillin unreliable
Resistance common among Staphylococcus
spp. and Gram-negative bacteria
Poor penetration into the prostate
Little supporting clinical trial data
Contraindicated in patients with allergy to
ß-lactams
Not recommended
Tetracyclines Cheap
Oral and parenteral forms available
Good activity aginst Chlamydia and
Mycoplasma
No activity against P. aeruginosa
Unreliable activity against coagulase-
negative staphylococci, E. coli, other
Enterobacteriaceae, and enterococci
Contraindicated in renal and liver failure
Risk of skin sensitization
Reserve for special
indications
Co-trimoxazole None
No advantage over trimethoprim
Risk of serious adverse events
Incidence of adverse events increases
with age
Not recommended
Trimethoprim Good penetration into prostate
Oral and parenteral forms available
Relatively cheap
Monitoring unnecessary
Active against most relevant pathogens
No activity against Pseudomonas, some
enterococci, and some Enterobacteriaceae
Consider
Macrolides Reasonable activity against Gram-positive
bacteria
Active against Chlamydia
Good penetration into prostate
Relatively nontoxic
Little supporting clinical trial data
Unreliable activity against Gram-negative
bacteria
Reserve for special
indications
Fluoroquinolones
(ofloxacin, ciprofloxacin)
Favourable pharmacokinetics
Excellent penetration into prostate
Good bioavailability
Equivalent oral and parenteral pharmaco-
kinetics (ofloxacin)
Good activity against ‘typical’ and ‘atypical’
pathogens and P. aeruginosa
Good safety profile
Possibility of drug interactions with
ciprofloxacin, especially at high doses
Recommended
of the cost of administration, the number of doses, the
need for monitoring, etc. The element of flexibility be-
tween intravenous and oral formulations, and therefore
the option for step-down therapy if this is required,
should also be considered as some drugs can only be given
parenterally or orally whilst others can be given by both
routes. For long-term treatment, which is often required
in chronic prostatitis, oral therapy is preferred.
Choice of Antibiotic Treatment
The advantages and disadvantages of the antibiotics
currently used for the treatment of chronic prostatitis are
shown in table 3. The aminoglycoside and ß-lactam anti-
biotics are not recommended since, compared with the
other antibiotic groups, they offer no therapeutic advan-
tages. Tetracyclines and macrolides are also not recom-
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mended for the treatment of CBP caused by ‘typical’ bac-
teria, due to their lack of, or unreliable, activity against
these bacteria. However, their good antibacterial activity
against Chlamydia (tetracyclines and macrolides) and
Mycoplasma (tetracyclines) makes them useful for the
treatment of infections caused by these bacteria. Co-tri-
moxazole can be excluded from the recommendations
because the sulphamethoxazole component offers no ther-
apeutic advantages over trimethoprim alone, it is associ-
ated with potentially serious adverse events and the inci-
dence of adverse events associated with co-trimoxazole
increases with age.
Thus, the antibiotics that should be considered for the
treatment of chronic prostatitis are trimethoprim and the
fluoroquinolones (table 3). A definitive comparison be-
tween these antibiotics is not possible due to the lack of
comparative clinical studies, and the lack of consistency
in the design of noncomparative clinical trials. However,
there are good reasons for recommending a fluoroquino-
lone for antibiotic treatment.
Of the fluoroquinolones currently available, ofloxacin
and ciprofloxacin can be recommended on the basis of
their spectrum of activity, which includes the most likely
pathogens, and pharmacokinetic profiles, which enable
good concentrations to be obtained in the prostate [28].
The following information therefore relates to these two
fluoroquinolones.
Firstly, they show good antibacterial activity against
most of the causative bacteria. As such, they are appro-
priate for the first-line treatment of both CBP and chronic
inflammatory prostatitis. This breadth of antibacterial
spectrum is not obtained with trimethoprim, macrolides
or tetracyclines. Secondly, the fluoroquinolones are am-
photeric drugs or zwitterions with a pKa value at both
acid and alkaline pH and achieve good penetration in the
prostate with high concentrations in prostatic tissue, pros-
tatic fluid and seminal fluid. Clinical studies have shown
that ofloxacin and ciprofloxacin levels achieved in pros-
tatic tissue, prostatic fluid, seminal fluid and ejaculate,
following both oral and intravenous administration, ex-
ceed the MICs of most of the common prostatitis patho-
gens [25, 27, 29–31].
Whilst the safety profiles of these two antibiotics are
generally similar, ofloxacin is associated with fewer drug
interactions than ciprofloxacin particularly at the high
doses recommended for the treatment of chronic prostati-
tis. In particular, it does not interact with xanthine drugs
such as theophylline and caffeine, whereas such interac-
tions do occur to a limited extent with ciprofloxacin [32–
34].
A number of clinical studies have shown ofloxacin and
ciprofloxacin to be of value in the treatment of CBP [21,
27, 29, 35–43]. However, it is difficult to make between-
study comparisons as study designs vary so markedly, a
common feature of trials of antibiotic efficacy in this
area.
Recommendations for Future Clinical Studies
There are a number of unresolved issues concerning
the diagnosis, therapeutic management and design of
clinical studies of chronic prostatitis. A number of clini-
cal trials are recommended to resolve or explain some of
these issues (table 4). In addition, because of the prob-
lems encountered when trying to compare clinical trials
with different study designs, we have proposed a stan-
dard design, based on that of Naber and Giamarellou
[12], which could be adopted and would assist in the
comparison of different studies (table 5). Also important
for standardization is the assessment of symptoms using
questionnaires or scoring instruments. Several authors
have described the use of symptom scoring instruments
for the assessment of prostatodynia and benign prostatic
hyperplasia [44–46] and Nickel and Sorensen [47] have
developed a symptom severity index and symptom fre-
quency questionnaire for the assessment of chronic non-
bacterial prostatitis patients. Similar symptom scoring
techniques should also be developed for the assessment
of CBP.
Conclusions
Summary of Recommendations
Chronic prostatitis is classified as CBP (culture-posi-
tive) and chronic inflammatory prostatitis (culture-nega-
tive). The diagnosis should be confirmed by the Meares
and Stamey segmented localization technique and un-
derlying urological conditions excluded by the following
tests: rectal examination, midstream urine culture and
residual urine.
Antibiotic therapy is recommended for acute, mainly
febrile, episodes in patients with chronic prostatitis; CBP
and chronic inflammatory prostatitis. Unless a patient
presents with fever and acute lower urinary tract symp-
toms, antibiotic treatment should not be initiated imme-
diately. The work-up, with the appropriate investigations,
should be done first within a reasonable time period
which, preferably, should not be longer than 1–2 weeks.
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Table 4. Unresolved issues in the diagnosis and antibiotic management of chronic prostatitis
Issue Action required
To clarify whether a suspected pathogen is definitely
related to the presenting symptoms and
inflammation
Prospective randomized trial of a fluoroquinolone vs.
placebo or nonspecific analgesic/inflammatory treat-
ment
B To determine the optimum duration of antibiotic
treatment once symptoms have resolved
A double-blind, randomized, comparative trial of
4 weeks’ treatment with an antibiotic vs. nonspecific
treatment, followed by similar trials using progressively
shorter treatment periods
C Follow-up period in most published studies is too
short for a chronic disease
All clinical trials of chronic prostatitis should include a
follow-up period of at least 6 months and preferably
1 year
D To confirm that clinical results with the fluoro-
quinolones are better than those with trimethoprim
Prospective randomized, comparative trial in patients
with moderate symptoms
E To improve the reproducibility and standardization
of the Meares and Stamey technique
Improve the methodology of the Meares and Stamey
technique, so that it is easier to standardize and the
results are more reproducible
Develop supporting investigations and correlate the re-
sults of the Meares and Stamey technique
Table 5. Proposed study design for
trials in chronic prostatitis Investigation Study
entry
During
treatment
Follow-up
1 month 6 months 1 year
+ + + +
Physical examination + +
Meares and Stamey test + + + +
MSU +1
Transrectal ultrasonography +
Blood chemistry + + (+)2
1 In case of treatment failure or relapse.
2 Only in case of previous pathological findings.
During this period, nonspecific treatment, such as appro-
priate analgesia to relieve symptoms, should be given.
The minimum duration of treatment should be 2–4
weeks. If there is no improvement in symptoms after this
time, the treatment should be stopped and reconsidered.
However, if there is improvement, treatment should be
continued for at least a further 2–4 weeks. Antibiotic
treatment should not be continued for several weeks with-
out any appraisal of whether it is effective. Of the antibi-
otics currently used for treatment, the fluoroquinolones
ofloxacin and ciprofloxacin are recommended because of
their favourable antibacterial spectrum and pharmacoki-
netic profile.
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